BIOMAT Database Logo BIOMAT Database Logo

Passive immunization with antibodies against tumor necrosis factor (TNF-alpha) protects from the lethality of splanchnic artery occlusion shock. 1992

F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Institute of Pharmacology, School of Medicine, University of Messina, Italy.

Splanchnic artery occlusion shock was induced in anesthetized rats by clamping splanchnic arteries for 45 min. Survival rate, serum and macrophage tumor necrosis factor (TNF-alpha), peritoneal macrophage phagocytosis, and killing activities were evaluated. Shocked rats died within 2 hr, whilst all sham-shocked rats survived more than 6 hr. Serum and macrophage TNF-alpha was undetectable in sham-shocked rats while shocked rats exhibited increased serum (110 +/- 5 U/ml 90 min after release of occlusion) and macrophage levels (122 +/- 4.5 U/ml 90 min after release of occlusion) of TNF-alpha. Furthermore, splanchnic artery occlusion shock produced cardiovascular changes, reduced macrophage phagocytosis (23 +/- 4.6%) and killing (6 +/- 1.1%) activities, and induced a massive necrosis of the ileum. A passive immunization with a hyperimmune serum containing antibodies against murine TNF-alpha significantly protected rats from the lethal effects of splanchnic artery occlusion shock, lowered serum TNF-alpha (6 +/- 2.1 U/ml), and completely reverted the impairment in peritoneal macrophage phagocytosis (48 +/- 4.8%) and killing (13 +/- 1.5%) activities. In addition passive immunization had beneficial effects on the cardiovascular changes occurring during splanchnic artery occlusion shock and prevented necrosis of the ileum induced by this model of shock. By contrast, pretreatment with polymyxin B, an "antiendotoxin" antibiotic, did not modify the lethal effects and the TNF-alpha production induced by splanchnic artery occlusion shock. Furthermore, endotoxin was undetectable in the blood of splanchnic artery occlusion shocked rats. These findings are consistent with the involvement of TNF-alpha in splanchnic artery occlusion shock and suggest that the cytokine represents an important mediator of non-septic shock.

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008297 Male Males
D011112 Polymyxin B A mixture of polymyxins B1 and B2, obtained from BACILLUS POLYMYXA strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for treatment of infections with gram-negative bacteria, but may be neurotoxic and nephrotoxic. Aerosporin,Polymyxin B Sulfate
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D001157 Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency. Arterial Obstructive Diseases,Arterial Occlusion,Arterial Obstructive Disease,Arterial Occlusions,Arterial Occlusive Disease,Disease, Arterial Obstructive,Disease, Arterial Occlusive,Obstructive Disease, Arterial,Occlusion, Arterial,Occlusive Disease, Arterial
D012769 Shock A pathological condition manifested by failure to perfuse or oxygenate vital organs. Circulatory Collapse,Circulatory Failure,Hypovolemic Shock,Collapse, Circulatory,Failure, Circulatory,Shock, Hypovolemic
D013152 Splanchnic Circulation The circulation of blood through the BLOOD VESSELS supplying the abdominal VISCERA. Mesenteric Circulation,Circulation, Mesenteric,Circulation, Splanchnic,Circulations, Mesenteric,Circulations, Splanchnic,Mesenteric Circulations,Splanchnic Circulations

Related Publications

F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
August 1985, Science (New York, N.Y.),
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats.
November 1992, Clinical and experimental immunology,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
[Building immune microsphere against tumor necrosis factor-alpha (TNF-alpha)].
December 2005, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
[Tumor necrosis factor alpha (TNF alpha)].
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Passive dual immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta maximally ameliorates acute aminonucleoside nephrosis.
February 1995, Clinical and experimental immunology,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice.
February 1997, American journal of respiratory and critical care medicine,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
September 1989, The Journal of experimental medicine,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha).
January 1992, Anticancer research,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
[Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies].
September 2000, Revue medicale de Liege,
F Squadrito, and D Altavilla, and M Ioculano, and G Calapai, and B Zingarelli, and A Saitta, and G M Campo, and A Rizzo, and A P Caputi
Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis.
July 1991, The Journal of clinical investigation,
Copied contents to your clipboard!